In contrast with T-cell counterparts, CD19-targeted CAR-NK cells have shown potent tumor-lytic effects in patients with B-cell lymphoid tumors, without inducing CRS, neurotoxicity, or GVHD 178. The gene discussed is CD19; the disease is congenital rubella syndrome.